{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:48:31Z","timestamp":1785527311853,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutic monoclonal antibodies. By using mouse and human B-T cell co-cultures, we report that CD19, an assumingly exclusive B cell marker, is transferred via trogocytosis when B cells activate T cells. In a B cell-driven model of experimental autoimmune encephalomyelitis, CD19\n                    <jats:sup>+<\/jats:sup>\n                    T cells expand and show enhanced features of activation, differentiation, and encephalitogenic potential ex vivo. Additionally, co-transfer of CD19 and functional IgM from B cells results in the gain of B cell function by T cells. In patients with chronic central nervous system (CNS) demyelination, CD19\n                    <jats:sup>+<\/jats:sup>\n                    T cells display a pro-inflammatory phenotype and are concomitantly depleted by inebilizumab, an approved anti-CD19 antibody, which raises important considerations for the therapeutic use of monoclonal antibodies overall. Finally, we report that myeloid cells acquire CD19 and functional IgM after phagocytosis of apoptotic B cells and thereby gain functional B cell properties. These findings highlight the commonness of membrane and antigen-transfer between cells, resulting in transmission of cellular function.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75534-3","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:44:00Z","timestamp":1785343440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B cell CD19 is transferred between immune cells in mice and humans"],"prefix":"10.1038","volume":"17","author":[{"given":"Jasmin","family":"Ochs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Schweineberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Thode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-1863","authenticated-orcid":false,"given":"Alica","family":"Blenkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Husseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-8065","authenticated-orcid":false,"given":"Tobias","family":"Bopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-0389","authenticated-orcid":false,"given":"Martin S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"75534_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1601565","volume":"2021","author":"E Uribe-Querol","year":"2021","unstructured":"Uribe-Querol, E. & Rosales, C. The multiple Roles of Trogocytosis in Immunity, the Nervous System, and Development. Biomed. Res. Int. 2021, 1601565 (2021).","journal-title":"Biomed. Res. Int."},{"key":"75534_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.immuni.2011.08.004","volume":"35","author":"EP Dopfer","year":"2011","unstructured":"Dopfer, E. P., Minguet, S. & Schamel, W. W. A new vampire saga: the molecular mechanism of T cell trogocytosis. Immunity 35, 151\u2013153 (2011).","journal-title":"Immunity"},{"key":"75534_CR3","doi-asserted-by":"crossref","unstructured":"Khawaja, Ashfaque Ahmed MAM, Yufeng, Xie and Jim, Xiang. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell. Mol. Immunol. 5, (2008).","DOI":"10.1038\/cmi.2008.32"},{"key":"75534_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi4632","volume":"14","author":"J Ochs","year":"2022","unstructured":"Ochs, J. et al. Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity. Sci. Transl. Med. 14, eabi4632 (2022).","journal-title":"Sci. Transl. Med."},{"key":"75534_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ana.26216","volume":"90","author":"C Quendt","year":"2021","unstructured":"Quendt, C., Ochs, J., Hausser-Kinzel, S., Hausler, D. & Weber, M. S. Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics. Ann. Neurol. 90, 834\u2013839 (2021).","journal-title":"Ann. Neurol."},{"key":"75534_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","volume":"265","author":"C Alcala","year":"2018","unstructured":"Alcala, C. et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J. Neurol. 265, 1690\u20131697 (2018).","journal-title":"J. Neurol."},{"key":"75534_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos, L. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.  Lancet 378, 1779\u20131787 (2011).","journal-title":"Lancet"},{"key":"75534_CR8","doi-asserted-by":"crossref","unstructured":"Florou, D., Katsara, M., Feehan, J., Dardiotis, E., Apostolopoulos, V. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sci. 10, (2020).","DOI":"10.3390\/brainsci10100758"},{"key":"75534_CR9","doi-asserted-by":"crossref","unstructured":"Stephen, L. Hauser, M. D., Emmanuelle Waubant, M. D., Ph.D., Douglas L. Arnold, M.D., Timothy Vollmer, M.D., Jack Antel, M.D., Robert J. Fox, M.D., Amit Bar-Or, M.D., Michael Panzara, M.D., Neena Sarkar PD, Sunil Agarwal, M.D., Annette Langer-Gould, M.D., Ph.D., and Craig H. Smith, M.D. B-Cell Depletion with Rituximab in Relapsing\u2013Remitting Multiple Sclerosis. The New Engl. J. Med. (2008).","DOI":"10.1056\/NEJMoa0706383"},{"key":"75534_CR10","doi-asserted-by":"crossref","unstructured":"Gingele, S. et al. Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients. Cells 8, (2018).","DOI":"10.3390\/cells8010012"},{"key":"75534_CR11","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.24998","volume":"60","author":"E Wilk","year":"2009","unstructured":"Wilk, E. et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 60, 3563\u20133571 (2009).","journal-title":"Arthritis Rheum."},{"key":"75534_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103352","volume":"57","author":"EP Flanagan","year":"2022","unstructured":"Flanagan, E. P. et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult. Scler. Relat. Disord. 57, 103352 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"75534_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton, J. E. Inebilizumab: first approval. Drugs 80, 1259\u20131264 (2020).","journal-title":"Drugs"},{"key":"75534_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.imlet.2015.11.002","volume":"168","author":"S Campana","year":"2015","unstructured":"Campana, S., De Pasquale, C., Carrega, P., Ferlazzo, G. & Bonaccorsi, I. Cross-dressing: an alternative mechanism for antigen presentation. Immunol. Lett. 168, 349\u2013354 (2015).","journal-title":"Immunol. Lett."},{"key":"75534_CR15","doi-asserted-by":"crossref","unstructured":"Doran, A. C., Yurdagul, A., Jr., Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254\u2013267 (2020).","DOI":"10.1038\/s41577-019-0240-6"},{"key":"75534_CR16","doi-asserted-by":"crossref","unstructured":"Facundo, D. Batista DIMSN. B cells acquire antigen from target cells after synapse formation. Nature, (2001).","DOI":"10.1038\/35078099"},{"key":"75534_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199594","volume":"14","author":"M Campos-Mora","year":"2023","unstructured":"Campos-Mora, M. et al. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. Front Immunol. 14, 1199594 (2023).","journal-title":"Front Immunol."},{"key":"75534_CR18","doi-asserted-by":"crossref","unstructured":"Akhila Bettadapur H. W. M. & Katherine S. Ralston. Biting off what can be chewed: trogocytosis in health, infection, and disease. Infection Immunity 88, (2020).","DOI":"10.1128\/IAI.00930-19"},{"key":"75534_CR19","doi-asserted-by":"crossref","unstructured":"Miyake K. & Karasuyama H. The role of trogocytosis in the modulation of immune cell functions. Cells 10, (2021).","DOI":"10.3390\/cells10051255"},{"key":"75534_CR20","doi-asserted-by":"publisher","first-page":"e00017","DOI":"10.1097\/IN9.0000000000000017","volume":"5","author":"D Kumar","year":"2023","unstructured":"Kumar, D., Pandit, R. & Yurdagul, A. Jr. Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis. Immunometabolism (Cobham) 5, e00017 (2023).","journal-title":"Immunometabolism (Cobham)"},{"key":"75534_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/imr.12537","volume":"277","author":"JM Blander","year":"2017","unstructured":"Blander, J. M. The many ways tissue phagocytes respond to dying cells. Immunol. Rev. 277, 158\u2013173 (2017).","journal-title":"Immunol. Rev."},{"key":"75534_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403150","volume":"15","author":"D Ngai","year":"2024","unstructured":"Ngai, D., Sukka, S. R. & Tabas, I. Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis. Front Immunol. 15, 1403150 (2024).","journal-title":"Front Immunol."},{"key":"75534_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-020-00796-z","volume":"24","author":"SR Guttikonda","year":"2021","unstructured":"Guttikonda, S. R. et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer\u2019s disease. Nat. Neurosci. 24, 343\u2013354 (2021).","journal-title":"Nat. Neurosci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75534-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:11:18Z","timestamp":1785521478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75534-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75534"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75534-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.W. received travel funding and\/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7588"}}